CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia
- PMID: 23633448
- DOI: 10.1002/cncr.28135
CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia
Comment on
-
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.Cancer. 2013 Aug 1;119(15):2728-36. doi: 10.1002/cncr.28136. Epub 2013 Apr 30. Cancer. 2013. PMID: 23633004 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources